J&J Independence iBOT Stair-Climbing Data Need Scrutiny, FDA Panel Says
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Independence Technology should prospectively evaluate user training for the Independence iBOT 3000 Advanced Mobility System specific to stair-climbing at home and test sites, FDA's Orthopaedic & Rehabilitation Devices Panel recommended Nov. 20 in Gaithersburg, Maryland
You may also be interested in...
J&J’s iBOT Wins Expedited FDA Approval, Faces Reimbursement Roadblocks
FDA will evaluate the need for labeling revisions to Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing wheelchair upon receipt of four semi-annual reports from the company
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.